In myelofibrosis, the introduction of reduced-intensity conditioning (RIC) preceding allogeneic stem cell transplantation (SCT) resulted in lower transplant-related mortality rates compared with myeloablative conditioning. However, lowering the intensity of conditioning may increase the risk of graft failure in myelofibrosis, although hitherto this has not been indisputably proven. We here report the outcome of 53 patients who underwent allogeneic SCT with different conditioning regimens (RIC and nonmyeloablative (NMA)) in three transplantation centers in the Netherlands. The cumulative incidence of graft failure within 60 days after SCT was high (28%), and this was primarily associated with the intensity of the conditioning regimen. Cumulative neutrophil engraftment at 60 days was lower in patients who received NMA conditioning compared with those who received RIC (56% vs 84%, P = 0.03). Furthermore, of six patients who received a second transplantation after graft failure, the three patients with RIC regimens subsequently engrafted, whereas the three patients who received a second NMA regimen did not. This study indicates that in myelofibrosis, NMA regimens result in high engraftment failure rates. We propose the use of more intensive conditioning regimens, incorporating busulfan or melphalan.
INTRODUCTION
In myelofibrosis (MF), the only potential curative treatment is allogeneic hematopoietic stem cell transplantation (allo SCT). Therefore, in patients with high-risk disease, this treatment should be considered even in the era of Janus kinase (JAK) inhibitors. However, it is currently unknown which type of conditioning leads to the best outcome. 1 Although myeloablative conditioning resulted in considerable overall survival (OS) rates of 47-61% at 5 years, treatment-related mortality (TRM)/non-relapse mortality rates were high, ranging from 27 to 48% at 1-5 years. [2] [3] [4] [5] [6] [7] [8] [9] The introduction of non-myeloablative-(NMA) and reduced-intensity conditioning (RIC) 10 regimens resulted in a lower TRM/non-relapse mortality rate of 16-30% at 1-5 years, with similar OS rates (31-67% after 3-5 years). 2, 6, 9, [11] [12] [13] However, randomized prospective data comparing myeloablative with RIC/NMA conditioning are lacking.
Furthermore, graft failure is an important issue in allo SCT for MF. In larger series, the incidence ranges from 2 to 24%. [5] [6] [7] 12, [14] [15] [16] Data on graft failure are not uniform and no definitive predictors for graft failure have yet been determined, but factors that have been associated with unsuccessful engraftment include: transplantation from an alternative donor (a (mis)matched unrelated donor, cord blood donor or haploidentical sources), inadequate numbers of CD34+ cells infused, degree of splenomegaly, selection of GvHD prophylaxis, degree of fibrosis with osteosclerosis and thrombocytopenia pre-transplantation. 2, 8, [14] [15] [16] [17] Moreover, the type of conditioning (RIC versus NMA or myeloablative) might affect the occurrence of graft failure. In a retrospective analysis, Gupta et al. did recently describe a trend toward superior survival in patients who received fludarabine/ melphalan compared with those who received fludarabine/ busulfan or TBI/fludarabine. However, these results were not statistically significant. Therefore, data considering the superiority of one regimen over the other are still lacking. 11 Here we report a retrospective analysis of 53 patients who were transplanted for myelofibrosis in three transplantation centers in the Netherlands, with an emphasis on conditioning regimens and engraftment outcome.
MATERIALS AND METHODS

Data source and patient selection
This study was conducted in three transplantation centers in the Netherlands. Patients with primary-or post-essential thrombocythemia/ polycythemia vera MF who underwent allogeneic SCT with RIC or NMA conditioning were included. Data were retrospectively collected. In addition, calreticulin (CALR) and myeloproliferative leukemia thrombopoietin receptor gene (MPL) sequencing was performed on banked samples. DNA was isolated using standard molecular techniques. CALR exon 9 was amplified as described previously, with minor adaptations. 18, 19 MPL exon 10 was amplified using either of the following primers: forward 5′-TAGGGGCTGGCTGGATG-3′ and reverse 5′-GGGGTCACAGAGCGAAC-3′ or forward 5′-CCGAAGTCTGACCCTTTTTG-3′ and reverse 5′-GACGGAGATCT GGGGTCAC-3′.
Definitions
The diagnosis was retrospectively confirmed in each patient using the 2008 WHO criteria. 20 The degree of marrow fibrosis was described by the local pathologist (scale: absent-mild-moderate-severe). Prognostic scoring was done using the Dynamic International Prognostic Scoring System (DIPSS) and the predictive transplant score devised by Bacigalupo et al. 21, 22 of 420 RBC transfusions, a spleen size 422 cm and the use of an alternative (that is, non-sibling) donor. Patients are categorized as low risk (0-1 factors) or high risk (⩾2 factors).
Based on HLA matching (molecular typing for HLA-A, -B, -C and -DRB1 and additionally for HLA-DQB1 in all but 3 cases), sibling and unrelated donors were considered matched (10/10 or 8/8) or mismatched (9/10 or 7/8). In cord blood donors, the HLA matching (molecular typing for HLA-A, -B and -DRB1) was at least 4/6. The intensity of conditioning regimens was categorized as RIC or NMA, according to a recent article by Bacigalupo et al. 10 Regimens combining fludarabine with low-dose TBI (⩽2 Gy) or cyclophosphamide-based regimens with a cumulative dosage o200 mg/kg were considered NMA. Regimens containing melphalan (140 mg/m2) or TBI in a higher dosage (42 Gy ⩽ 5) were classified as RIC.
Neutrophil engraftment was defined as the first of three consecutive days with an ANC40.5 × 10 9 /L or the first day with a count of 41.0 × 10 9 /L. Platelet recovery was defined as the first of three consecutive measurements (obtained over at least 7 days) with a platelet count 420 × 10 9 /L, without any platelet transfusions at the time or in the week before. Both neutrophil and platelet engraftment required the presence of a complete (490%) or partial but rising (at least 10% at first measurement) donor chimerism. Primary graft failure was diagnosed if neutrophil engraftment was not reached by day +60. Secondary graft failure was defined as loss of previous engraftment (that is, loss of neutrophil engraftment and/or loss of donor chimerism). Response was graded according to the International Working Group consensus criteria. 23 Relapse was defined as loss of previous best response (that is, CR, PR or clinical improvement (CI)) and only patients with successful engraftment were considered to be at risk. TRM was defined as death due to any cause but myelofibrosis. OS was defined as time from SCT to death from any cause.
End points and statistical analysis
Primary end points of the study were engraftment and primary graft failure. Other end points of interest were OS, TRM, GvHD and treatment response.
Differences between groups were compared using the Mann-Whitney test in case of continuous variables and the Fisher's exact test in case of proportions. Probabilities of engraftment, OS and TRM were calculated using the Kaplan-Meier estimator. For calculation of cumulative neutrophil engraftment, patients were censored at time of death or last follow-up or at time of a second SCT. For calculation of TRM, patients were censored in case of death related to myelofibrosis, a second SCT or at last follow-up. For OS, patients were censored at last follow-up. The log-rank test was used for univariate comparisons. Hazard ratios were computed with the Cox proportional hazards model. All P-values are two-sided and considered significant if o0.05. Calculations were performed in SPSS version 22.0.
RESULTS
Patient-, disease-and transplantation-related characteristics Fifty-three patients were enrolled. Their characteristics are shown in Table 1 . Median age at SCT was 57 years (range 36-69) and median time from diagnosis to SCT was 28 months (range 1-322). Data on mutational status were available in 42 patients. Of these, 22 patients (52%) carried a JAK2 mutation. Among the JAK2-negative patients, mutations in the MPL and calreticulin genes were found in 3 and 10 patients, respectively. In seven patients (17%) none of these mutations were found (triple negative). Risk classification according to DIPSS was low in 5% (n = 3), intermediate-1 in 42% (n = 22), intermediate-2 in 42% (n = 22) and high in 2% (n = 1). According to the predictive transplant score, equal numbers of patients scored a low and high risk (both 45.5%, n = 24). DIPSS and predictive transplant scores could not be evaluated in 9% (n = 5) owing to missing data. Owing to the small number of DIPSS low-and high-risk patients, the DIPSS groups were collapsed into low/intermediate-1 and intermediate-2/high groups for further analysis. Previous treatment had been prescribed in 64% of patients (n = 34), being described in detail in Table 1 .
Characteristics of transplantation are shown in Table 2 . Transplantations were performed between September 2003 and August 2013. The main stem cell source was peripheral blood (n = 47, 89%) and the majority of donors were matched siblings (MSD; n = 18, 34%) and matched unrelated donors (matched unrelated donor; n = 22, 42%). Cord blood transplantation was performed in 7% (n = 4). NMA conditioning was given to 20 patients (38%) and consisted of either (1) fludarabine 30 mg/m 2 per day for 3 days and TBI 2 Gy or (2) fludarabine 25 mg/m 2 /day for 5 days and cyclophosphamide 500 mg/m 2 /day for 5 days (n = 1). RIC regimens were given to 33 patients (62%) and included (1) cyclophosphamide 60 mg/kg for 1 day, fludarabine 40 mg/m 2 / day for 4 days and TBI 4 Gy (n = 15) and (2) fludarabine 30 mg/m 2 / day for 5 days and melphalan 70 mg/m 2 /day for 2 days (n = 18). Anti-thymocyte globulin (ATG; 2 mg/kg/day for 3-4 days) was added in the case of an unrelated donor in all patients that received fludarabine/TBI and in 11 of 13 patients who received fludarabine/melphalan. GvHD prophylaxis consisted of cyclosporine alone (n = 2), cyclosporine with mycophenolatemofetil (n = 31), mycophenolic acid (n = 6) or prednisolone (n = 3), cyclosporine with prednisolone and mycophenolatemofetil (n = 9) or mycophenolic acid (n = 1) or none (n = 1).
Transplantation outcomes
Primary end point: engraftment. The cumulative neutrophil engraftment was 57% (95% confidence interval (CI): 43-70%) at 28 days and 75% (95% CI: 63-87%) at 100 days (Tables 3 and 4) . Chimerism analysis had not been performed in three of these patients, but as they all experienced acute GvHD (aGvHD) they were considered to have engrafted. Four patients died without engraftment within 60 days after SCT. Causes of death in these patients were infection (n = 2), heart failure (n = 1) and aGvHD (n = 1). The cumulative incidence of primary graft failure at 60 days was 28% (95% CI: 15-40%). Of the 12 patients who were classified as primary graft failure, one patient engrafted spontaneously at day +63. Another patient received a donor lymphocyte infusion and engrafted at day +231. Two patients received a stem cell boost and engrafted at day +154 and +240, respectively. Four patients had sustained graft failure until time of death (n = 2) or last follow-up (n = 2). The remaining four patients with primary graft failure received a second SCT (see below). In addition, three patients experienced secondary graft failure. One of them died and the other two received a second SCT (see below).
In univariate analysis, the cumulative neutrophil engraftment at 60 days was significantly lower in patients who received NMA conditioning compared with those who received RIC (56% vs 84%, P = 0.03) with a hazard ratio of 2.1 (95% CI: 1.1-4.0) (Figure 1) . Notably, the three patients who experienced secondary graft failure had also received NMA conditioning. Within the RIC group, we found that the cumulative neutrophil engraftment at 60 days was higher in patients who received fludarabine/melphalan, compared with those who received fludarabine/cyclophosphamide/TBI (100% vs 65%, P = 0.001). No significant differences in neutrophil engraftment were seen between the group with a MSD and the group with an unrelated donor. Because of the small number of cord blood transplantations (n = 4), these were not included in the univariate analysis. Two of these patients successfully engrafted at day +55 and +56, respectively. One patient died of heart failure at day +27 and one experienced primary graft failure. They had all received a RIC regimen. No significant differences in cumulative neutrophil engraftment were found when comparing number of CD34+ cells infused (⩽2.5 vs 42.5x10 6 /L), spleen status (enlarged vs not enlarged/post splenectomy), platelet count pre-transplantation (⩽100 vs 4100x10 
Abbreviations: CALR = calreticulin; DIPSS = Dynamic International Prognostic Scoring System; ET = essential thrombocythemia; JAK2 = Janus kinase 2; MPL = myeloproliferative leukemia, thrombopoietin receptor gene; MPN nos = myeloproliferative neoplasm not otherwise specified; NMA = nonmyeloablative; PV = polycythemia vera; RIC = reduced-intensity conditioning; SCT = stem cell transplantation. The predictive transplant score was described by Bacigalupo et al. 22 Degree of marrow fibrosis as described by the local pathologist. a Data on all three mutations were available in 42 patients. All percentages shown are based on this number of patients. The autologous stem cell transplantation had been performed for the treatment of a lymphoblastic T-cell lymphoma. Abbreviations: ATG = anti-thymocyte globulin; HCT = hematopoietic cell transplantation; NMA = non-myeloablative; RIC = reduced-intensity conditioning. − indicates not applicable.
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Secondary end points. GvHD: Data on aGVHD were available in all but two patients (n = 51). Of these, 32 patients (63%) experienced aGvHD. In the RIC group, a significantly higher incidence of aGvHD was found compared with in the NMA group (75% and 42%, respectively, P = 0.04). No difference in aGvHD was found between regimens with or without ATG. Twenty-six patients experienced chronic GvHD (49%). No significant differences in incidence were found when comparing conditioning regimens (RIC vs NMA), donor types (MSD vs unrelated donor vs cord blood) and use of ATG. Transplant-related mortality and OS: Cumulative incidence of TRM was 26% (95% CI: 14-38%) at 6 months and 43% (95% CI: 28-58%) at 1 year. In univariate analysis, a significantly higher TRM was found in the group with an unrelated donor, compared with the MSD group (54% vs 24%, P = 0.04). OS was 57% (95% CI: 44-71%) at 1 year and 49% (95% CI: 34-64%) at 2 years. OS was higher in patients with a low predictive transplant score, compared with the high-risk group (69% vs 46%, P = 0.04). For the TRM, no such difference was found. A higher OS was seen in patients with a MSD compared with those with an unrelated donor, but this was not statistically significant (71% (95% CI 50-93%) vs 48% (95% CI 31-66%) at 1 year, P = 0.06). No significant differences in TRM or OS were found when comparing conditioning regimens (RIC vs NMA), DIPSS score (low/intermediate-1 vs intermediate-2/high), mutational status (JAK2+ vs MPL+ vs CALR+ vs triple negative), spleen status (enlarged vs not enlarged/postsplenectomy), age at SCT (⩽60 vs 460 years) or platelet count pre-transplantation (⩽100 vs 4100 × 10 9 /L). Second transplantations: As described above, six patients (four with primary graft failure and two with secondary graft failure) received a second allogeneic SCT. Stem cell source was peripheral blood (n = 5) or bone marrow (n = 1) and the median number of CD34+ cells infused was 7.2x10 6 /kg (range 6.5-13). Conditioning was NMA in three patients, including (1) cyclophosphamide 60 mg/kg/day for 2 days (n = 1), (2), cyclophosphamide 60 mg/kg/day for 2 days and TBI 2 Gy (n = 1) or (3) fludarabine 30 mg/m 2 /day for 3 days and TBI 2 Gy (n = 1). The other three patients received RIC, consisting of either (1) fludarabine 30 mg/ m 2 /day for 5 days and melphalan 70 mg/kg/day for 2 days (n = 2) or (2) cyclophosphamide 60 mg/kg for 1 day, fludarabine 40 mg/ m 2 /day for 4 days and TBI 4 Gy (n = 1). Anti-thymocyte globulin was added in the case of an unrelated donor. The three patients conditioned with the NMA regimen experienced graft failure again (primary n = 2, secondary n = 1). Two of them died and one is alive with disease progression at 60 months after the second transplantation. The three patients who received the RIC regimen engrafted and obtained PR, with a follow-up of 26, 27 and 37 months, respectively.
DISCUSSION
Here we report the results from a retrospective analysis of 53 patients who received an allogeneic SCT in three transplantation centers in the Netherlands over a 10-year period. The most striking finding was the high cumulative incidence of graft failure within 60 days after SCT (28%) as compared with previous reports. In an univariate analysis, this was shown to be primarily associated with the intensity of the conditioning regimen used. Cumulative neutrophil engraftment was higher in the group that received RIC compared with in the NMA group, with a hazard ratio of 2.1. Also, the three patients who experienced secondary graft failure had received NMA conditioning. Moreover, from the six patients who received a second transplantation after (primary or secondary) graft failure, the three patients receiving a RIC regimen subsequently engrafted, whereas the three patients receiving a second NMA conditioning regimen did not. The difference in incidence of primary graft failure between the RIC and NMA group cannot be explained by differences in baseline characteristics. There were slight differences in DIPSS score and stem cell source, but these factors were not associated with the time to neutrophil engraftment in univariate analysis. There was no statistically significant difference in previous use of hydroxyurea between the RIC and NMA groups. Also, no other significant differences in time to neutrophil engraftment were found when comparing spleen status, mutational status, number of CD34+ cells infused and platelet count pre-transplantation. The number of cord blood transplantations was too small to evaluate the influence on engraftment, but excluding these patients did not change the findings described above.
We previously reported that engraftment may indeed be affected by the type of conditioning, possibly through the different extent of increase in stromal-derived factor-1α. 24 Stromal-derived factor-1α has a key regulatory role in stem cell homing as well as in restoration of the hematopoietic stem cell niche after conditioning. In a murine model, conditioning-induced increases in stromal-derived factor-1α levels were found to attract CXCR4-positive megakaryocytes. A concomitant increase in PDGF-β and basic fibroblast growth factor (bFGF) levels, known to Abbreviations: CI = confidence interval; HCT = hematopoietic cell transplantation; TRM = treatment-related mortality.
a Data on aGvHD were missing in two cases.
b Best recorded response was defined as the best response that was documented at any given time point, but before the start of any other myelofibrosis treatment. If a bone marrow biopsy was not performed after transplantation, response could not be graded higher than PR. Patients with primary graft failure (n = 12) were excluded from this analysis. c Cases were categorised as not evaluable in case of death within 60 days after transplantation or in case of pronounced variability in blood values (for example, in the case of multiple comorbidities and/or continuous high-dose immune suppressants).
Effect of conditioning on graft failure in myelofibrosis S Slot et al promote osteoblast proliferation, led to restoration of the hematopoietic stem cell niche as demonstrated by local engraftment of transplanted hematopoietic stem cells. 25 We described that a more dose-intense regimen consisting of fludarabine and cyclophosphamide resulted in an increase in bone marrow stromal-derived factor-1α levels, whereas fludarabine in combination with low-dose TBI did not. A concomitant difference in hematopoietic recovery was suggested.
To our knowledge, an influence of the difference between RIC or NMA regimens on engraftment in myelofibrosis has not been previously described. However, in most studies conditioning was myeloablative and/or RIC and no distinction was made between RIC and NMA. In concordance with our results, a recent report that focused solely on graft failure reported a higher relative risk of graft failure after RIC and NMA compared with myeloablative conditioning. These results remained significant in multivariate analysis and the risk was higher for NMA than for RIC (RR 4.5 and 2.6, respectively). However, in this study allogeneic SCT had been performed for multiple (hematologic and non-hematologic) indications and only a small number of MF patients was included (n = 21). 26 Other indirect support for our hypothesis stems from the reports by Kröger et al. They used a RIC regimen, incorporating fludarabine, busulfan and ATG, and reached the lowest graft failure rates reported to date (2-5%). 12, 27 In contrast, Ballen et al. Abbreviations: cy = cyclophosphamide; DIPSS = Dynamic International Prognostic Scoring System; Flu = fludarabine; JAK2 = Janus kinase 2; Mel = melphalan; MSD = matched sibling donor; NMA = non-myeloablative; PTS = predictive transplant score; RIC = reduced-intensity conditioning; SCT = stem cell transplantation; TRM = treatment-related mortality; UD = unrelated donor. − indicates not applicable. Values are shown as percentages (95% CI). 
Type of conditioning
Non-myeloablative Reduced-intensity Non-myeloablativecensored Reduced-intensitycensored Figure 1 . The figure shows the cumulative incidence of neutrophil engraftment in the group that received NMA conditioning (blue line) and in the group that received RIC (green line), respectively. The P-value was calculated with the log-rank test and is two-sided.
found a higher incidence of graft failure in patients who received RIC compared with those who received NMA conditioning. In their study, a comparable categorization of conditioning regimens was made, based on the recommendations of the Regimen-Related Toxicity Working Committee. Primary graft failure occurred in 7 out of 60 patients who received RIC or NMA conditioning, of whom six had received RIC and one had received NMA conditioning.
14 This difference in findings might be explained by the higher number of bone marrow transplantations in their cohort (no information on infused CD34+ count is given, but on average this is lower in bone marrow transplantation compared with peripheral blood). Also, a difference in the definition of graft failure may have been of influence (lack of neutrophil engraftment at day +35, compared with day +60 in our study), as five patients (9%) in our study engrafted between day +35 and day +60 and the majority of them (80%) had received RIC.
Another important issue in allogeneic SCT is the prediction of outcome in the individual patient. Multiple prognostic scoring models have been described; however, most were not designed for use in the transplantation setting. In a recent review by Alchalby et al. it is described that prognosis does differ significantly between DIPSS low, intermediate (-1 and -2) and high-risk groups, but no significant differences in survival are found between intermediate-1 and intermediate-2 risk groups. 28 This might explain why in our cohort, mainly consisting of patients with an intermediate-1 or -2 risk, we did not find a significant association between DIPSS score and OS. In contrast, we did find a significantly higher OS in the group with a low predictive transplant score. This scoring model was described by Bacigalupo and colleagues in 2010, but has not often been used in other studies. 22 Unfortunately, in the review by Alchalby, the predictive transplant score could not be examined due to missing data regarding number of transfused RBCs and degree of splenomegaly. It would therefore be interesting to incorporate this scoring model into future studies. Finally, it has recently been shown that mutational status influences survival outcomes in MF. 18, 29 No such correlation was found in our cohort.
In conclusion, several studies have demonstrated that reducing the intensity of conditioning regimens in allogeneic transplantation for MF leads to lower non-relapse mortality. However, graft failure is still a major issue and to find predictive factors for this complication, documentation should be more detailed and uniform across studies. Our study indicates that NMA regimens, only incorporating fludarabine and low-dose TBI, result in high rates of engraftment failure and should not be used in patients with MF. Whether administration of ruxolitinib pre-transplantion will improve this (as might be expected because of reduction of both spleen size and inflammatory cytokines) will have to be proven. A small study by Jaekel et al. 30 indeed showed a low graft failure rate (1 out of 14 patients, 7%). We suggest that, awaiting the results of trials now investigating the role of ruxolitinib, more intensive conditioning regimens, for example, those incorporating busulfan or melphalan, should be used.
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